Literature DB >> 7742440

Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole.

P C Iwen1, D M Kelly, E C Reed, S H Hinrichs.   

Abstract

Candida krusei is a cause of invasive candidiasis (IC), with numerous cases reported among leukemia patients after bone marrow transplantation and treatment with fluconazole. The relation between fluconazole therapy and IC remains controversial. In a retrospective review covering 5 years, we identified 203 cases of IC, 71 (35%) of which were due to non-albicans species. Eight cases were caused by C. krusei: four of the patients involved had leukemia, two had breast cancer, one had end-stage liver disease, and one had undergone abdominal trauma. None of these patients received fluconazole. Surveillance cultures detected colonization with C. krusei before the onset of symptoms in seven cases. The median time from colonization to IC diagnosis was 10 days. Of six patients with neutropenia, five were neutropenic at IC diagnosis. Concomitant infections were common; four patients had both bacteremia and invasive aspergillosis. C. krusei was considered the immediate cause of five of the seven deaths among this group of patients. These eight cases extend the range of immunocompromised conditions in which IC caused by C. krusei develops in the absence of fluconazole therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7742440     DOI: 10.1093/clinids/20.2.342

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

1.  Emerging Issues in Nosocomial Fungal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

Review 2.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

Review 3.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center.

Authors:  C R Boschman; U R Bodnar; M A Tornatore; A A Obias; G A Noskin; K Englund; M A Postelnick; T Suriano; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 5.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

6.  Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006.

Authors:  Shawn R Lockhart; Debra Wagner; Naureen Iqbal; Peter G Pappas; David R Andes; Carol A Kauffman; Lisa M Brumble; Susan Hadley; Randall Walker; James I Ito; John W Baddley; Tom Chiller; Benjamin J Park
Journal:  J Clin Microbiol       Date:  2011-05-11       Impact factor: 5.948

7.  Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999).

Authors:  Amar Safdar; Vishnu Chaturvedi; Brian S Koll; Davise H Larone; David S Perlin; Donald Armstrong
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital.

Authors:  Y F Berrouane; L A Herwaldt; M A Pfaller
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 9.  Fungal infections: a growing threat.

Authors:  D M Dixon; M M McNeil; M L Cohen; B G Gellin; J R La Montagne
Journal:  Public Health Rep       Date:  1996 May-Jun       Impact factor: 2.792

Review 10.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.